Development of dds using hollow bio-nanoparticles and their commercialization

0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS. © 2006, THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM. All rights reserved.

Cite

CITATION STYLE

APA

Kondo, A., Kuroda, S. ichi, Tanizawa, K., Seno, M., & Ueda, M. (2006). Development of dds using hollow bio-nanoparticles and their commercialization. Drug Delivery System, 21(4), 435–443. https://doi.org/10.2745/dds.21.435

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free